Frontlight ResearchEarly access
CompletedNo phase
Prediction of Reverse Remodeling and Outcome in Patients With Severe Secondary Mitral Valve Regurgitation Undergoing Transcatheter Edge-to-edge Mitral Valve Repair
Key facts
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 39 people enrolled
- Started
- 4 Aug 2021
- Ended
- 30 Sept 2026
- Type of study
- Interventional
- Treatments tested
- Cardiac magnetic resonance imaging before the procedure
- Transcatheter mitral edge-to-edge repair.
- Record updated
- 6 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients with severe secondary MR characterized, according to the European guidelines and recommendations, by a regurgitant volume ≥30 mL/beat or an effective regurgitant orifice ≥20 mm²
- Symptomatic patients with New York Heart Association Class ≥II
- Left ventricular ejection fraction between 15% and 50%
- Optimal standard of care therapy for heart failure according to investigator
- Not eligible for a mitral surgery intervention according to the Heart Team
- Patients who have the ability to understand the requirements of the study and provide written consent/assent to participate and agree to abide by the study requirements
Who cannot take part
- Patients with untreated severe concomitant valve disease (e.g. severe tricuspid valve regurgitation, aortic stenosis)
- The patient has a medical condition, serious concurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up
- The patient has contraindications to CMR, including: Implanted non-CMR conditional metallic implants, pacemaker, intracardiac defibrillator, neurostimulator, epicardial pacemaker leads, or any abandoned leads, ferromagnetic aneurysm clip, ferromagnetic halo device, cochlear implants, implanted infusion pumps or severe claustrophobia
- The patient is clinically unstable or has stage D congestive heart failure or inability to lay flat for 60 minutes
- Severe impaired renal function (GFR < 15 ml/min)
- Participants younger than 18 years
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The investigators' hypothesis is that CMR tissue characterization and myocardial function analysis acquired by CMR feature tracking technique predict reverse remodeling in patients with severe secondary mitral regurgitation (MR) undergoing transcatheter mitral edge-to-edge repair.
The group in the trial
- Treatment ArmTreatment being tested
Patients undergoing transcatheter mitral edge-to-edge repair in this single-arm study.
Treatment: Cardiac magnetic resonance imaging before the procedure and Transcatheter mitral edge-to-edge repair.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 November 2026